• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Blinatumomab as bridging therapy in two children with B-cell acute lymphoblastic leukemia complicated by invasive fungal disease].[博纳吐单抗作为两名合并侵袭性真菌病的B细胞急性淋巴细胞白血病儿童的桥接治疗]
Zhongguo Dang Dai Er Ke Za Zhi. 2023 Dec 15;25(12):1282-1286. doi: 10.7499/j.issn.1008-8830.2306142.
2
Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.Blinatumomab 作为桥接治疗在儿童 B 细胞急性淋巴细胞白血病合并侵袭性真菌病中的应用。
Br J Haematol. 2022 Sep;198(5):887-892. doi: 10.1111/bjh.18314. Epub 2022 Jun 21.
3
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.儿童移植后复发/难治性B前体急性淋巴细胞白血病通过使用T细胞接合双特异性抗体博纳吐单抗治疗显示出持久缓解。
Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.
4
The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing.下一代测序检测到的儿童 B 细胞急性淋巴细胞白血病患者中blinatumomab 清除可测量残留病的疗效。
Cancer Med. 2023 Dec;12(24):21978-21984. doi: 10.1002/cam4.6771. Epub 2023 Dec 8.
5
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B-cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia.在小儿 B 细胞前体急性淋巴细胞白血病发生严重毒性的情况下,Blinatumomab 作为进一步治疗的桥梁:来自以色列儿童白血病研究组的报告。
Pediatr Blood Cancer. 2019 Oct;66(10):e27898. doi: 10.1002/pbc.27898. Epub 2019 Jul 2.
6
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Blinatumomab 治疗成人复发/难治性 B 前体急性淋巴细胞白血病患者的安全性和疗效:一项多中心、单臂、2 期研究。
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
7
Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.博纳吐单抗:填补成人复发/难治性B细胞急性淋巴细胞白血病治疗空白
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S2-5. doi: 10.1016/j.clml.2016.02.001.
8
Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); , Following Blinatumomab Therapy.婴儿 B 淋巴细胞白血病伴 t(1;11)(p32;q23); 经blinatumomab 治疗后出现谱系转换。
Pediatr Dev Pathol. 2021 Jul-Aug;24(4):378-382. doi: 10.1177/10935266211001308. Epub 2021 Mar 22.
9
FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.FDA 补充批准:blinatumomab 用于治疗复发/难治性前体 B 细胞急性淋巴细胞白血病。
Oncologist. 2018 Nov;23(11):1366-1371. doi: 10.1634/theoncologist.2018-0179. Epub 2018 Jul 17.
10
Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.博纳吐单抗:用于前体B细胞急性淋巴细胞白血病的首款双特异性T细胞衔接器。
Ann Pharmacother. 2015 Sep;49(9):1057-67. doi: 10.1177/1060028015588555. Epub 2015 Jun 3.

本文引用的文献

1
Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.Blinatumomab 作为桥接治疗在儿童 B 细胞急性淋巴细胞白血病合并侵袭性真菌病中的应用。
Br J Haematol. 2022 Sep;198(5):887-892. doi: 10.1111/bjh.18314. Epub 2022 Jun 21.
2
Antifungal use in children with acute leukaemia: state of current evidence and directions for future research.儿童急性白血病的抗真菌药物使用:当前证据状况和未来研究方向。
J Antimicrob Chemother. 2022 May 29;77(6):1508-1524. doi: 10.1093/jac/dkac060.
3
Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia.博纳吐单抗作为儿童难治性/复发性急性淋巴细胞白血病造血干细胞移植的桥接疗法
Cancers (Basel). 2022 Jan 17;14(2):458. doi: 10.3390/cancers14020458.
4
Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia.小儿急性淋巴细胞白血病的诊断与治疗进展
J Clin Med. 2021 Apr 29;10(9):1926. doi: 10.3390/jcm10091926.
5
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 与化疗治疗高危初发 B 细胞急性淋巴细胞白血病患儿无事件生存的效果:一项随机临床试验。
JAMA. 2021 Mar 2;325(9):843-854. doi: 10.1001/jama.2021.0987.
6
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.Blinatumomab 巩固化疗后与化疗对初发 B 细胞急性淋巴细胞白血病儿童、青少年和年轻成人患者无病生存的影响:一项随机临床试验。
JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669.
7
A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.Blinatumomab 治疗急性淋巴细胞白血病的系统评价:用新方法解决老问题。
Ann Pharmacother. 2021 Oct;55(10):1236-1253. doi: 10.1177/1060028020988411. Epub 2021 Jan 13.
8
Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.Blinatumomab 和 inotuzumab 免疫疗法在复发或难治性 B 急性淋巴细胞白血病患儿中的临床应用。
Pediatr Blood Cancer. 2021 Jan;68(1):e28718. doi: 10.1002/pbc.28718. Epub 2020 Oct 24.
9
[The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision)].《血液系统疾病和癌症患者侵袭性真菌病诊断与治疗中国指南(第6版)》
Zhonghua Nei Ke Za Zhi. 2020 Oct 1;59(10):754-763. doi: 10.3760/cma.j.cn112138-20200627-00624.
10
Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.希腊在儿童复发和难治性急性淋巴细胞白血病患者中使用 Blinatumomab 的经验见解。
Neoplasma. 2020 Nov;67(6):1424-1430. doi: 10.4149/neo_2020_200128N93. Epub 2020 Jul 23.

[博纳吐单抗作为两名合并侵袭性真菌病的B细胞急性淋巴细胞白血病儿童的桥接治疗]

[Blinatumomab as bridging therapy in two children with B-cell acute lymphoblastic leukemia complicated by invasive fungal disease].

作者信息

Liu Xiao-Fei, Tang Xue, Wang Lu-Lu, Wang Ying, Liu Shi-Lin, Zhou Gui-Chi, Li Tong-Hui, Mai Hui-Rong

机构信息

Department of Hematology and Oncology, Shenzhen Children's Hospital, Shenzhen, Guangdong 518034, China (Mai H-R, Email: maihuirong@163. com).

出版信息

Zhongguo Dang Dai Er Ke Za Zhi. 2023 Dec 15;25(12):1282-1286. doi: 10.7499/j.issn.1008-8830.2306142.

DOI:10.7499/j.issn.1008-8830.2306142
PMID:38112148
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10731972/
Abstract

This article reports two cases of children with B-cell acute lymphoblastic leukemia (B-ALL) complicated by invasive fungal disease (IFD) who received bridging treatment using blinatumomab. Case 1 was a 4-month-old female infant who experienced recurrent high fever and limb weakness during chemotherapy. Blood culture was negative, and next-generation sequencing (NGS) of peripheral blood, bronchoalveolar lavage fluid, and cerebrospinal fluid were all negative. Chest CT and cranial MRI revealed obvious infection foci. Case 2 was a 2-year-old male patient who experienced recurrent high fever with multiple inflammatory masses during chemotherapy. Candida tropicalis was detected in peripheral blood and abscess fluid using NGS, while blood culture and imaging examinations showed no obvious abnormalities. After antifungal and blinatumomab therapy, both cases showed significant improvement in symptoms, signs, and imaging, and B-ALL remained in continuous remission. The report indicates that bridging treatment with blinatumomab in children with B-ALL complicated by IFD can rebuild the immune system and control the underlying disease in the presence of immunosuppression and severe fungal infection.

摘要

本文报告了2例B细胞急性淋巴细胞白血病(B-ALL)合并侵袭性真菌病(IFD)的儿童患者,他们接受了使用博纳吐单抗的桥接治疗。病例1是一名4个月大的女婴,在化疗期间反复出现高热和肢体无力。血培养阴性,外周血、支气管肺泡灌洗液和脑脊液的二代测序(NGS)均为阴性。胸部CT和头颅MRI显示有明显感染灶。病例2是一名2岁男性患者,在化疗期间反复出现高热并伴有多个炎性肿块。通过NGS在外周血和脓肿液中检测到热带念珠菌,而血培养和影像学检查未显示明显异常。经过抗真菌和博纳吐单抗治疗后,两例患者的症状、体征和影像学表现均有显著改善,B-ALL持续缓解。该报告表明,对于合并IFD的B-ALL儿童患者,使用博纳吐单抗进行桥接治疗可以在免疫抑制和严重真菌感染的情况下重建免疫系统并控制基础疾病。